For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
CorMedix Inc (NASDAQ: CRMD) closed the day trading at $13.06 down -0.31% from the previous closing price of $13.1. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 2.61 million shares were traded. CRMD stock price reached its highest trading level at $13.32 during the session, while it also had its lowest trading level at $12.795.
Ratios:
For a better understanding of CRMD, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.06. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 7.82. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On March 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $18.Leerink Partners initiated its Outperform rating on March 07, 2025, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 31 ’24 when Mistry Erin bought 1,500 shares for $9.99 per share. The transaction valued at 14,985 led to the insider holds 52,011 shares of the business.
Hurlburt Elizabeth sold 140,027 shares of CRMD for $1,565,670 on Nov 14 ’24. The EVP now owns 45,397 shares after completing the transaction at $11.18 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the Officer of the company, bought 140,027 shares for $11.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 974915968 and an Enterprise Value of 784639360. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.49, and their Forward P/E ratio for the next fiscal year is 6.51. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.03 while its Price-to-Book (P/B) ratio in mrq is 4.42. Its current Enterprise Value per Revenue stands at 6.459 whereas that against EBITDA is 15.739.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.76, which has changed by 1.6067865 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $4.68. The 50-Day Moving Average of the stock is 5.07%, while the 200-Day Moving Average is calculated to be 22.72%.
Shares Statistics:
Over the past 3-months, CRMD traded about 2.32M shares per day on average, while over the past 10 days, CRMD traded about 4501310 shares per day. A total of 74.62M shares are outstanding, with a floating share count of 66.88M. Insiders hold about 10.40% of the company’s shares, while institutions hold 46.13% stake in the company. Shares short for CRMD as of 1753920000 were 10679715 with a Short Ratio of 4.61, compared to 1751241600 on 9650210. Therefore, it implies a Short% of Shares Outstanding of 10679715 and a Short% of Float of 14.46.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is $0.64, with high estimates of $0.84 and low estimates of $0.49.
Analysts are recommending an EPS of between $1.83 and $1.29 for the fiscal current year, implying an average EPS of $1.56. EPS for the following year is $2.26, with 5.0 analysts recommending between $2.73 and $1.69.
Revenue Estimates
5 analysts predict $53.58M in revenue for the current quarter. It ranges from a high estimate of $64.17M to a low estimate of $47M. As of the current estimate, CorMedix Inc’s year-ago sales were $11.46MFor the next quarter, 5 analysts are estimating revenue of $84.61M. There is a high estimate of $99.9M for the next quarter, whereas the lowest estimate is $66M.
A total of 5 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $238.1M, while the lowest revenue estimate was $193.3M, resulting in an average revenue estimate of $217.01M. In the same quarter a year ago, actual revenue was $43.47MBased on 5 analysts’ estimates, the company’s revenue will be $342.41M in the next fiscal year. The high estimate is $422.28M and the low estimate is $273M.
